drugset / Trial / NCT01774604

Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

NCT01774604

Phase 3 Terminated 449 enrolled Dartmouth-Hitchcock Medical Center
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to assess whether peri-procedural administration of rectal indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.

Timeline

Start
2013-01
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Indomethacin Small molecule 100 mg Rectal

Indications